Philips to acquire BioTelemetry, Inc. for USD 72.00 per share; implied enterprise value of USD 2.8 billion (approx. EUR 2.3 billion)Acquisition is a strong fit with Philips’ strategy to transform the delivery of healthcare: combination of Philips’ leading patient monitoring position in the hospital with BioTelemetry’s leading cardiac

Press Release         To Our shareholders: As the year is drawing to a close, we once again find ourselves planning for the future, but also reflecting on the events of 2020. I am sure we can all agree that 2020 was filled wi

Ingenion Medical Limited, today, announces it has been awarded nearly £100,000 in grant funding from Innovate UK, the country’s innovation agency. Ingenion will use the proceeds over the next six months to gain a CE Mark for its CymActive™ urinary catheter, a novel medical device to treat male patients suffering from chronic urinary retention. Ingenion’s CEO Edward Cappabianca said, “Our technology’s proprietary, patent-pending magnetic

MARKHAM, Ontario, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common Share”) for the month of December 2020, which is payable on January 15, 2021 to shareholders of record at the close of business

FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging and medical informatics solutions, announced today that UroPartners, the largest urology practice in Illinois and top five in the nation, has chosen to standardize on the Persona CT Computed Tomography (CT) system to accelerate their oncology treatment planning capabilities. Designed and built in the U.S., the Persona CT is an innovative CT system from Fujifilm in partnership with Analogic. The system offers advan

TransEnterix, Inc., a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that Southern Surgical Hospital has entered into an agreement to lease and utilize a Senhance® Surgical System. “We are pleased to support Southern Surgical Hospital in advancing care with the addition of the Senhance Surgical System,” said Anthony Fernando, President and Chief Executive Officer at Tr

The European Society for Medical Oncology (ESMO), the leading professional organisation for medical oncology, has updated the Clinical Practice Guidelines for Dermatological Toxicities Related to Anticancer Agents to include the recommendation of scalp cooling for the prevention of chemotherapy-induced alopecia (CIA) as a Category IIB recommendation. A multidisciplinary group of experts from institutions and countries across Europe, the USA and Australia authored the updated guideli

Medovate is proud to announce conclusion of an agreement with Mercury Medical to distribute its medical device SAFIRA™ (SAFer Injection for Regional Anesthesia) – a move that will now provide 100% coverage across the United States of America. Despite the ongoing global COVID-19 pandemic which has closed many country borders, Medovate has successfully secured a deal with one of the United States’ largest distribution partners for their FDA-cleared device.

Spinal Elements, a spine technology company, today announced the acquisition of the assets of Benvenue Medical, Inc., a developer of MIS lumbar fusion systems. Among the assets are the Luna® XD multi-expandable lumbar fusion device and the Orbit™ Articulating Discectomy System. Benvenue had recently introduced the next generation Luna XD system based upon years of experience with a prior generation device. The Luna XD system allows an implant to be surgically delivered thr

Okami Medical Inc., a medical device company, today announced the expansion of its LOBO™ Vascular Occlusion System product line with the U.S. FDA 510(k) clearance of the LOBO-5 Vascular Occluder. The LOBO (LOw-profile Braided Occluder) system is uniquely designed to provide interventional physicians with a single-device, "one-and-done" solution for the occlusion of a wide range of peripheral arterial targets.  The LOBO system combines neurovascular-derived HDBRA